Paper Details

  1. Home
  2. Paper Details

Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma.

Author: JiXuebing, PeiXiaohong, XuRui, YuYongqiang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This retrospective study compared the clinical effect and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in patients with intermediate-advanced hepatocellular carcinoma. TACE plus lenvatinib showed better disease control, reduced tumor markers, and stabilized liver function compared to TACE plus sorafenib. However, lenvatinib was associated with higher incidences of diarrhea, hand-foot syndrome, hypertension, and rash.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the clinical effect and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate-advanced hepatocellular carcinoma. METHODS: In this retrospective study, 84 patients with intermediat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006802/

データ提供：米国国立医学図書館（NLM）

A New Approach to Liver Cancer Treatment

This study explores the potential of combining transarterial chemoembolization (TACE) with lenvatinib, a medication used to treat liver cancer. It's like trying to quench the thirst of a desert with a new type of water source. The researchers compared this combination with TACE combined with sorafenib, another medication commonly used for liver cancer. They wanted to see which approach was more effective.

The Results Show Promise

The findings suggest that TACE combined with lenvatinib may be more effective than TACE combined with sorafenib. It's like finding a well that provides a more abundant and refreshing water supply. The combination led to better tumor control, reduced levels of tumor markers, and improved liver function.

Hope for Liver Cancer Patients

This research offers hope for individuals battling liver cancer. It's like discovering a new oasis in the desert, bringing much-needed relief from the heat. It suggests that there may be new and improved treatment options available.

Dr. Camel's Conclusion

This study underscores the importance of ongoing research in the fight against liver cancer. It's a reminder that we must continue to explore new and innovative approaches to treatment.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

36915764

DOI: Digital Object Identifier

PMC10006802

Related Literature

Article Analysis
・Side Effects of lenvatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.